Keyriched-1 - A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)
NCT03988036
Rekrutierend
Studienbeginn:
August 2020
Letztes Update: 04.09.2020
Letztes Update: 04.09.2020
Wirkstoff(e):
Pembrolizumab, Trastuzumab Biosimilar ABP 980...
Indikation: Breast Neoplasms
Locations: Tübingen, Muenchen, Frankfurt...
Indikation: Breast Neoplasms
Locations: Tübingen, Muenchen, Frankfurt...